Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Update on key adverse events

Benedito A. Carneiro*, Jason B. Kaplan, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Current treatment recommendations for chronic myeloid leukemia (CML) are guided by results from multiple clinical trials involving tyrosine kinase inhibitors that target BCR-ABL1. Consideration of the unique clinical benefits and potential risks associated with each tyrosine kinase inhibitor approved for the treatment of CML is crucial for physicians when recommending the most appropriate therapy for each patient. Monitoring for and prompt management of adverse events may increase adherence to therapy and optimize patient outcomes. Here we provide an overview of the efficacy and safety of tyrosine kinase inhibitors approved for the treatment of CML, as well as recommendations for the management of key adverse events reported with these agents in clinical trials involving patients with CML.

Original languageEnglish (US)
Pages (from-to)457-479
Number of pages23
JournalExpert Review of Hematology
Volume8
Issue number4
DOIs
StatePublished - Aug 1 2015

Keywords

  • adverse events
  • bosutinib
  • chronic myeloid leukemia
  • dasatinib
  • imatinib
  • nilotinib
  • ponatinib
  • safety
  • tolerability
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Update on key adverse events'. Together they form a unique fingerprint.

Cite this